Chronic kidney disease (CKD) and cardiometabolic diseases represent significant pharmaceutical markets. Due to the advancing age of baby-boomers, obesity and a sedentary life style within industrialized societies, the number of patients requiring CKD and cardiometabolic drug interventions continues to expand. In the U.S., the Center for Disease Control estimates that 30% of adults are clinically obese. By the year 2020 the U.S. Census Bureau is projecting that 17% of the population will be over the age of 65. Age is a significant risk factor for cardiometabolic disease. The National Institutes of Health is projecting that type II diabetes, diabetes linked to insulin resistance, is expected to strike one in three Americans during their lifetime. These related diseases and their life altering impact will likely continue to dominate the drug development focus in the developed world. Even in India, diabetes is projected to affect one out of every three people.